CBM 801
Alternative Names: CBM-801Latest Information Update: 27 Sep 2024
Price :
$50 *
At a glance
- Originator CellionBioMed
- Class Anti-inflammatories
- Mechanism of Action Small-conductance calcium-activated potassium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammatory bowel diseases; Multiple sclerosis
Most Recent Events
- 25 Sep 2024 Preclinical trials in Inflammatory bowel diseases in South Korea (unspecified route) before September 2024 (CellionBioMed pipeline, September 2024)
- 29 Dec 2022 Preclinical trials in Multiple sclerosis in South Korea (unspecified route) (CellionBioMed pipeline, December 2022)